Researchers identified circulating extracellular vesicle proteins that both predict clinical outcomes and actively interfere with therapies targeting CLDN18.2. The findings describe a mechanism by which vesicle components can undermine chimeric antigen receptor T-cell activity and monoclonal antibody performance in gastrointestinal cancers. The work points to a potential biomarker strategy for stratifying patients likely to benefit and a therapeutic direction for countering vesicle-driven resistance. Clinically, the study offers a clearer pathway for explaining differential responses in CLDN18.2-driven trials.